Coronary artery disease: Are β-blockers truly helpful in patients with CAD?

Nature Reviews Cardiology

Volumn 10, Issue 1, 2013, Pages 11-12

  Danchin, Nicolas ^a   Laurent, Stéphane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84871775165     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.159     Document Type: Article

References (10)

1. Freemantle, N., Cleland, J., Young, P., Mason, J. & Harrison, J. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318, 1730-1737 (1999). (Pubitemid 29290470)
2. Antman, E. M. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 117, 296-329 (2008).
3. Steg, P. G. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33, 2569-2619 (2012).
4. Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341-1381 (2006). (Pubitemid 43998110)
5. Bangalore, S. et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308, 1340-1349 (2012).
6. Shu, D. F., Dong, B. R., Lin, X. F., Wu, T. X. & Liu, G. J. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur. J. Prev. Cardiol. 19, 330-341 (2012).
7. Tuppin, P. et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch. Cardiovasc. Dis. 103, 363-375 (2010).
8. Boutouyrie, P. et al. Pharmacological modulation of arterial stiffness. Drugs 71, 1689-1701 (2011).
9. Ong, K. T. et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376, 1476-1484 (2010).
10. Bangalore, S., Parkar, S., Grossman, E. & Messerli, F. H. A meta-analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100, 1254-1262 (2007). (Pubitemid 47498283)